There's actually also physical strain on the host in terms of gastrointestinal distress and liver distress over the long term. These drugs are quite safe, but this is still a factor.
The reason, though, is that Genoceas vax isn't through all the hurdles yet, and bodies like the FDA don't care about stuff that isn't on market.
But I get your point. As a race, I take Gens vax as the benchmark. But there's more to it than that. It's also the business acumen and the deal offered. I think we have a much better team from that POV now.
hsv2 final results, page-57
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $363.6M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |